Collapse all
The Business Model Canvas reveals a high-barrier, specialized diagnostic service that shifts psychedelic therapy from a 'one-size-fits-all' timing to a precision medicine approach. Success depends on deep integration with clinical imaging centers and the ability to translate complex fMRI data into actionable clinical windows for therapists.
4 Clinical Imaging Centers Partnerships with facilities providing high-resolution fMRI hardware to conduct the longitudinal scans. Psychedelic Clinics (e.g., Mindleap) Treatment providers who integrate the monitoring service into their patient care protocols. Academic Research Institutions Collaborations with neuroimaging labs to refine the specific connectivity markers of the hippocampal-DMN axis. Regulatory Bodies (FDA/EMA) Engagement to validate the plasticity marker as a recognized clinical endpoint for psychedelic-assisted therapy. 4 Precision Functional Mapping Executing longitudinal fMRI scans to track the desynchronization between the anterior hippocampus and the DMN. Biomarker Analysis Processing raw neuroimaging data to quantify the reduction in functional connectivity (FC) over time. Therapeutic Window Prediction Translating FC data into a 'plasticity score' that tells clinicians exactly when to start psychotherapy. Clinical Validation Running longitudinal studies to correlate the hippocampal-DMN marker with actual patient recovery rates. 3 Proprietary Analysis Pipeline Software algorithms capable of precision mapping and longitudinal tracking of specific brain network changes. Neuroimaging Expertise Specialized data scientists and neuroradiologists skilled in functional connectivity analysis. Longitudinal Dataset A proprietary database of brain state changes post-psilocybin to refine the predictive model. 3 Precision Timing for Therapy Eliminates guesswork in psychotherapy scheduling by identifying the peak proplastic state of the patient's brain. Objective Efficacy Verification Provides clinical proof of the 'therapeutic window' via neuroanatomical markers rather than relying solely on subjective patient reports. Reduced Treatment Failure Increases the success rate of psychedelic interventions by ensuring psychotherapy occurs while the brain is most receptive to change. 2 B2B Clinical Integration Deeply embedded partnership with clinics where the monitor is a standard part of the treatment package. Consultative Reporting Providing clinicians with interpreted reports that translate complex fMRI data into simple 'Go/No-Go' therapy windows. 3 Clinical Partnerships Direct integration into the workflow of specialized mental health centers like Mayo Clinic. Medical Conferences Presenting data at psychiatry and neurology symposiums to drive adoption among early adopters. API Integration Providing a digital dashboard that plugs into the Electronic Health Records (EHR) of psychedelic clinics. 3 Specialized Psychedelic Clinics Private providers (e.g., Mindleap) seeking to differentiate their care through precision medicine. Academic Medical Centers Large-scale institutions like Mayo Clinic conducting clinical trials or high-end psychiatric care. Pharmaceutical R&D Companies developing new psychedelic compounds who need a biomarker to prove efficacy in clinical trials. 3 Imaging Overhead High costs associated with fMRI machine time and technician labor for longitudinal visits. Computational Costs Expenses for high-performance computing required to process complex functional mapping data. Specialized Talent High salaries for PhD-level neuroscientists and data engineers. 3 Per-Patient Diagnostic Fee A flat fee charged to the clinic for the full longitudinal monitoring package per patient. SaaS Subscription Monthly recurring revenue for access to the plasticity tracking dashboard and predictive analytics. Clinical Trial Licensing Licensing the biomarker tool to pharma companies for use as a primary endpoint in drug trials. The idea identifies specific high-value beneficiaries like Mayo Clinic, making it appropriate to map the value proposition and revenue streams. · Generated 2026-09-05 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated